India’s Contract Research, Development, and Manufacturing Organization (CRDMO) sector is experiencing a significant surge, emerging as a key player in the global pharmaceutical market. Recently, a report by Jefferies India revealed that the Indian CRDMO sector has already achieved revenues of approximately $3 billion, with a notable compound annual growth rate (CAGR) of 14% over the past five years.
This growth story has attracted global investors, evident from the sector’s current market capitalization ranging from $40-50 billion. Despite a temporary disruption caused by the Covid-19 pandemic, the future outlook appears robust. Jefferies projects an 18% CAGR for the CRDMO sector between FY25 and FY30, driven by factors such as a promising drug pipeline, the strategic diversification of Big Pharma through the “China+1” approach, and expanding opportunities in weight-loss and Type 2 diabetes medications.
A pivotal factor propelling this momentum is the shift away from reliance on Chinese CRDMOs, a trend that has gained traction due to geopolitical uncertainties. With a notable move towards alternative supply chains, Indian firms are poised to benefit significantly. Jefferies estimates an annual opportunity of $700 million under the base case scenario, potentially escalating to $1.4 billion in an optimistic scenario. This strategic realignment is anticipated to persist for over a decade, although risks remain should Big Pharma continue to engage in licensing deals with Chinese counterparts.
The landscape is further enriched by Big Pharma’s initiatives, with leading Indian companies venturing into advanced therapies. Noteworthy examples include Divi’s Laboratories’ involvement in the “blockbuster GLP-1 pipeline,” Cohance’s investments in antibody-drug conjugates (ADCs), and the robust late-stage portfolios of Piramal and Sai Life Sciences.
An additional growth avenue identified in the report pertains to the weight-loss and diabetes drug segment. Projections indicate that the demand for intermediates related to newer medications like Tirzepatide and Orforglipron could culminate in a $1.2 billion market by the year 2030.
Sai Life Sciences emerges as a standout choice in the report, lauded for its integrated services and strong global presence, with anticipated revenue and EBITDA CAGRs of 15% and 24% respectively between FY25 and FY28. Furthermore, the report provides strategic insights by initiating coverage on Cohance with a “Buy” rating, upgrading Divi’s Laboratories due to its exposure in the GLP-1 segment, maintaining a positive stance on Piramal Pharma for its value proposition, while exercising caution with regard to Syngene, Gland, and Laurus Labs due to limited triggers or operational hurdles.
In conclusion, the Jefferies report underscores the burgeoning potential of India’s CRDMO sector, positioning it as a key player in the global pharmaceutical landscape. With a robust growth trajectory, strategic alignments, and a diverse portfolio of offerings, Indian firms are poised to capitalize on the evolving dynamics of the industry, presenting lucrative opportunities for investors and stakeholders alike.
Takeaways:
– India’s CRDMO sector is a $3 billion revenue industry, exhibiting a remarkable 14% CAGR over the past five years.
– Strategic diversification by Big Pharma and the “China+1” strategy are driving the growth of the Indian CRDMO sector.
– Emerging opportunities in weight-loss and diabetes drugs, coupled with advanced therapies, are propelling the sector’s expansion.
– Key players like Sai Life Sciences are well-positioned for significant growth, offering integrated services and a strong presence in global markets.
Tags: antibody-drug conjugates
Read more on thehindubusinessline.com